Compare

Genmab A/S/€GMAB

1D1W1M3M6MYTD1Y5YMAX

About Genmab A/S

Genmab A/S is a biotechnology company based in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics for the treatment of cancer. The company's core products include a range of proprietary technologies and therapeutic antibodies, most notably DARZALEX (daratumumab), which is used in the treatment of multiple myeloma. Genmab collaborates with various pharmaceutical companies to advance its research and expand its product offerings. Founded in 1999, the company leverages its proprietary antibody technologies, including the DuoBody and HexaBody platforms, to create differentiated therapies. Its strategic partnerships and emphasis on cutting-edge research provide it with a notable position in the biopharmaceutical industry.
Ticker
€GMAB
Sector
Health
Primary listing
XGAT
Employees
3,119
Headquarters
Copenhagen, Denmark
Website
www.genmab.com

Genmab A/S Metrics

BasicAdvanced
€29B
43.57
€11.23
0.69
-

What the Analysts think about Genmab A/S

Analyst ratings (Buy, Hold, Sell) for Genmab A/S stock.
Analyst projections of the future price of Genmab A/S stock.

Bulls say / Bears say

Revenue rose 25% in the first half of 2026, and Genmab raised its full-year revenue and adjusted operating profit outlook. That points to strong current demand and improving near-term earnings momentum. (Genmab A/S)
Epcoritamab plus R-CHOP cut the risk of progression or death by 51% in a Phase 3 trial for newly diagnosed DLBCL. If regulators approve the combination, it could broaden the drug’s role and commercial reach. (Genmab A/S)
Rina-S produced durable, clinically meaningful Phase 2 results in ovarian cancer, adding promise to Genmab’s potential future product growth. Further late-stage evidence is still needed to confirm its commercial potential. (BioSpace)
Genmab remains heavily reliant on DARZALEX royalties, but its US patents expire in 2029. Analysts cited by BioSpace expect those royalties to fall sharply after expiry, creating a major hole for the pipeline to replace. (BioSpace)
The Merus acquisition left Genmab with $5.5 billion of borrowings, and interest expense was $174 million in the first half of 2026. Those financing costs reduce the benefit of operating growth and limit financial flexibility. (U.S. Securities and Exchange Commission)
Rina-S faces an unresolved trade-secret lawsuit from AbbVie, which is seeking damages and injunctive relief. AbbVie withdrew its related US trade complaint but said it intended to resume the court case, leaving legal uncertainty around a key pipeline asset. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.

Genmab A/S Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Genmab A/S Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.